董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stuart A. Arbuckle | 男 | Director | 59 | 未披露 | 未持股 | 2021-03-01 |
| Kristine Peterson | 女 | Director | 65 | 9.88万美元 | 未持股 | 2021-03-01 |
| Richard J. Wallace | 男 | Director | 74 | 9.18万美元 | 未持股 | 2021-03-01 |
| Stuart A. Arbuckle | 男 | Director | 59 | 8.18万美元 | 未持股 | 2021-03-01 |
| Stephen C. McCluski | 男 | Chairman of the Board | 73 | 12.48万美元 | 未持股 | 2021-03-01 |
| Dean J. Mitchell | 男 | Director | 69 | 8.88万美元 | 未持股 | 2021-03-01 |
| Mark J. Enyedy | 男 | President, Chief Executive Officer and Director | 57 | 391.76万美元 | 未持股 | 2021-03-01 |
| Mark Goldberg | 男 | Director | 70 | 8.88万美元 | 未持股 | 2021-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anna Berkenblit | 女 | Senior Vice President and Chief Medical Officer | 51 | 180.87万美元 | 未持股 | 2021-03-01 |
| Thomas Ryll | 男 | Senior Vice President, Technical Operations | 60 | 156.68万美元 | 未持股 | 2021-03-01 |
| Stacy Coen | 女 | Senior Vice President and Chief Business Officer | 50 | 未披露 | 未持股 | 2021-03-01 |
| Susan Altschuller | 女 | Senior Vice President and Chief Financial Officer | 39 | 未披露 | 未持股 | 2021-03-01 |
| Theresa G. Wingrove | 女 | Senior Vice President, Regulatory Affairs and Quality | 63 | 未披露 | 未持股 | 2021-03-01 |
| Mark J. Enyedy | 男 | President, Chief Executive Officer and Director | 57 | 391.76万美元 | 未持股 | 2021-03-01 |
董事简历
中英对照 | 中文 | 英文- Stuart A. Arbuckle
-
自2012年以来，StuartA.Arbuckle一直担任制药公司Vertex Pharmaceuticals Incorporated的执行Vice President和首席商务官。在此之前，他在制药公司安进公司工作了8年，担任多个商业领导职务，包括Vice President和安进肿瘤业务部总经理，负责Aranesp、Neulasta和Neupogen的销售与市场营销工作，并领导了XGEVA和Nplate的成功推出。他还担任Vice President和地区总经理，并领导安进公司在日本以及亚洲、中东和非洲新兴市场的业务拓展。在加入Amgen之前，他在制药公司GlaxoSmithKline plc及其前身公司工作了15年多，在那里他在销售与市场营销中担任越来越重要的职务。Arbuckle先生也是RhythmPharmaceuticals，Inc.的董事在过去五年中，Arbuckle先生还曾担任Cerulean Pharma Inc.与DareBioscience，Inc.合并前的董事
Stuart A. Arbuckle has served as Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals Incorporated, a pharmaceutical company, since 2012. Prior to that he spent eight years at Amgen Inc., a pharmaceutical company, in multiple commercial leadership roles, including Vice President and General Manager for Amgen's oncology business unit, where he was responsible for sales and marketing efforts for Aranesp, Neulasta and NEUPOGEN, and led the successful launches of XGEVA and Nplate. He also served as Vice President and Regional General Manager and led efforts to expand Amgen's presence in Japan and emerging markets in Asia, the Middle East and Africa. Prior to joining Amgen, he spent more than 15 years at GlaxoSmithKline plc, a pharmaceutical company, and its predecessors, where he held positions of increasing responsibility in sales and marketing. Mr. Arbuckle is also a director of Rhythm Pharmaceuticals, Inc. Within the past five years, Mr. Arbuckle also served as a director of Cerulean Pharma Inc. prior to its merger with Dare Bioscience, Inc. - 自2012年以来，StuartA.Arbuckle一直担任制药公司Vertex Pharmaceuticals Incorporated的执行Vice President和首席商务官。在此之前，他在制药公司安进公司工作了8年，担任多个商业领导职务，包括Vice President和安进肿瘤业务部总经理，负责Aranesp、Neulasta和Neupogen的销售与市场营销工作，并领导了XGEVA和Nplate的成功推出。他还担任Vice President和地区总经理，并领导安进公司在日本以及亚洲、中东和非洲新兴市场的业务拓展。在加入Amgen之前，他在制药公司GlaxoSmithKline plc及其前身公司工作了15年多，在那里他在销售与市场营销中担任越来越重要的职务。Arbuckle先生也是RhythmPharmaceuticals，Inc.的董事在过去五年中，Arbuckle先生还曾担任Cerulean Pharma Inc.与DareBioscience，Inc.合并前的董事
- Stuart A. Arbuckle has served as Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals Incorporated, a pharmaceutical company, since 2012. Prior to that he spent eight years at Amgen Inc., a pharmaceutical company, in multiple commercial leadership roles, including Vice President and General Manager for Amgen's oncology business unit, where he was responsible for sales and marketing efforts for Aranesp, Neulasta and NEUPOGEN, and led the successful launches of XGEVA and Nplate. He also served as Vice President and Regional General Manager and led efforts to expand Amgen's presence in Japan and emerging markets in Asia, the Middle East and Africa. Prior to joining Amgen, he spent more than 15 years at GlaxoSmithKline plc, a pharmaceutical company, and its predecessors, where he held positions of increasing responsibility in sales and marketing. Mr. Arbuckle is also a director of Rhythm Pharmaceuticals, Inc. Within the past five years, Mr. Arbuckle also served as a director of Cerulean Pharma Inc. prior to its merger with Dare Bioscience, Inc.
- Kristine Peterson
-
Kristine Peterson，2010年11月加入Amarin，担任非执行董事。她拥有27年多的医药行业经验，包括曾在 Bristol-Myers Squibb任职20年，期间负责各种治疗领域的销售和一般管理，包括领导心血管和代谢性疾病的业务团队。2009年6月以来，她一直是Valeritas, Inc的首席执行官，该公司是一家医疗技术公司，致力于创新药物传输解决方案的开发和商业化，其主导产品适用于糖尿病的治疗。在加入Valeritas之前的2006年5月至2009年6月间，她曾在Johnson & Johnson担任生物技术业务部部长；2004年8月至2006年5月，在该公司担任执行副总裁；2003年5月至2004年8月，在 Biovail Corporation担任商业运营部高级副总裁。她目前是Valeritas,Inc、ImmunoGen,Inc、生物技术工业组织和Greater Philadelphia Life Sciences CongressValeritas的董事。她持有伊利诺大学的市场营销学工商管理硕士学位。
Kristine Peterson,has served on board of directors since November 2017. Ms. Peterson most recently served as Chief Executive Officer for Valeritas, Inc. from 2009 to 2016. Prior to joining Valeritas, Ms. Peterson was Company Group Chair of the biotechnology group at Johnson & Johnson from 2006 until 2009, where she was responsible for Commercial, Research & Development, and biologics manufacturing for oncology, immunology and cell therapy, and was Executive Vice President of Pharmaceutical Group Strategic Marketing from 2004 to 2006. Previously, she served as President and Senior Vice President, Commercial Operations for Biovail Corporation. Earlier in her career, Kristine spent 20 years at Bristol-Myers Squibb Company in a variety of senior roles across multiple disease areas, including running their cardiovascular and metabolics business unit. Ms. Peterson has served on the boards of directors of ArriVent BioPharma since April 2024 and Enanta Pharmaceuticals since September 2017, and she previously served on the boards of directors for Amarin Corporation plc, EyePoint Pharmaceuticals, ImmunoGen, Inc. and Paratek Pharmaceuticals. Additionally, she previously served as a senior advisor to the Healthcare Businesswomen's Association and a Member of the Biotechnology Industry Organization Board. Ms. Peterson has a B.S. and an M.B.A. from the University of Illinois at Urbana-Champaign. - Kristine Peterson，2010年11月加入Amarin，担任非执行董事。她拥有27年多的医药行业经验，包括曾在 Bristol-Myers Squibb任职20年，期间负责各种治疗领域的销售和一般管理，包括领导心血管和代谢性疾病的业务团队。2009年6月以来，她一直是Valeritas, Inc的首席执行官，该公司是一家医疗技术公司，致力于创新药物传输解决方案的开发和商业化，其主导产品适用于糖尿病的治疗。在加入Valeritas之前的2006年5月至2009年6月间，她曾在Johnson & Johnson担任生物技术业务部部长；2004年8月至2006年5月，在该公司担任执行副总裁；2003年5月至2004年8月，在 Biovail Corporation担任商业运营部高级副总裁。她目前是Valeritas,Inc、ImmunoGen,Inc、生物技术工业组织和Greater Philadelphia Life Sciences CongressValeritas的董事。她持有伊利诺大学的市场营销学工商管理硕士学位。
- Kristine Peterson,has served on board of directors since November 2017. Ms. Peterson most recently served as Chief Executive Officer for Valeritas, Inc. from 2009 to 2016. Prior to joining Valeritas, Ms. Peterson was Company Group Chair of the biotechnology group at Johnson & Johnson from 2006 until 2009, where she was responsible for Commercial, Research & Development, and biologics manufacturing for oncology, immunology and cell therapy, and was Executive Vice President of Pharmaceutical Group Strategic Marketing from 2004 to 2006. Previously, she served as President and Senior Vice President, Commercial Operations for Biovail Corporation. Earlier in her career, Kristine spent 20 years at Bristol-Myers Squibb Company in a variety of senior roles across multiple disease areas, including running their cardiovascular and metabolics business unit. Ms. Peterson has served on the boards of directors of ArriVent BioPharma since April 2024 and Enanta Pharmaceuticals since September 2017, and she previously served on the boards of directors for Amarin Corporation plc, EyePoint Pharmaceuticals, ImmunoGen, Inc. and Paratek Pharmaceuticals. Additionally, she previously served as a senior advisor to the Healthcare Businesswomen's Association and a Member of the Biotechnology Industry Organization Board. Ms. Peterson has a B.S. and an M.B.A. from the University of Illinois at Urbana-Champaign.
- Richard J. Wallace
-
Richard J. Wallace，2004年起，担任制药公司GlaxoSmithKline plc（GSK）的研发部高级副总裁，直到2008年退休。此前，1992-2002，他曾在GSK及其前身公司、子公司担任过各种行政职务。加入GSK之前，他在Bristol-Myers Squibb Company工作了8年，在Johnson & Johnson工作了7年，担任过营销、销售、制造及综合管理方面的多个职务。他也是GNC Corporation的董事。在过去的五年，他曾担任Avigen, Inc.、Bridgehead International Ltd. 和 Clinical Data的董事。我们相信，在一些大型制药公司愈益重要的多个职务的任职经历，足以使他胜任本公司董事会的工作。由于他有着上述的经验，他对于美国和国际范围内的药物开发行业，有着深刻的理解。通过在其它公司的任职经历，他获得了丰富的企业治理经验。
Richard J. Wallace served as a Senior Vice President for Research and Development at GlaxoSmithKline plc GSK, a pharmaceutical company, from 2004 to his retirement in 2008. Prior to that, he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace’s experience prior to joining GSK included eight years with Bristol-Myers Squibb Company, a pharmaceutical company, and seven years at Johnson & Johnson, a healthcare products and pharmaceutical company, in assignments spanning marketing, sales, manufacturing, and general management. Mr. Wallace is also a director of GNC Holdings, Inc. - Richard J. Wallace，2004年起，担任制药公司GlaxoSmithKline plc（GSK）的研发部高级副总裁，直到2008年退休。此前，1992-2002，他曾在GSK及其前身公司、子公司担任过各种行政职务。加入GSK之前，他在Bristol-Myers Squibb Company工作了8年，在Johnson & Johnson工作了7年，担任过营销、销售、制造及综合管理方面的多个职务。他也是GNC Corporation的董事。在过去的五年，他曾担任Avigen, Inc.、Bridgehead International Ltd. 和 Clinical Data的董事。我们相信，在一些大型制药公司愈益重要的多个职务的任职经历，足以使他胜任本公司董事会的工作。由于他有着上述的经验，他对于美国和国际范围内的药物开发行业，有着深刻的理解。通过在其它公司的任职经历，他获得了丰富的企业治理经验。
- Richard J. Wallace served as a Senior Vice President for Research and Development at GlaxoSmithKline plc GSK, a pharmaceutical company, from 2004 to his retirement in 2008. Prior to that, he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace’s experience prior to joining GSK included eight years with Bristol-Myers Squibb Company, a pharmaceutical company, and seven years at Johnson & Johnson, a healthcare products and pharmaceutical company, in assignments spanning marketing, sales, manufacturing, and general management. Mr. Wallace is also a director of GNC Holdings, Inc.
- Stuart A. Arbuckle
-
Stuart A. Arbuckle，博士，他自2015年1月起担任Vertex Pharmaceuticals Incorporated的全球研究执行副总裁兼首席科学官，并于2012年5月至2014年12月成为Vertex Pharmaceuticals Incorporated的董事会成员。Altshuler博士是Broad Institute的四个创始成员之一，这是一项研究合作哈佛大学，麻省理工学院，怀特黑德研究所和哈佛医院。他于2003年至2014年12月担任该研究所医学和人口遗传学项目主任，并于2009年至2014年12月担任该研究所的副主任和首席学术官。Altshuler博士加入哈佛医学院和马萨诸塞州综合医院2000年至2008年12月担任遗传学和医学教授学术等级。他于2012年至2014年12月在麻省理工学院担任生物学兼职教授。Altshuler博士获得学士学位来自麻省理工学院，获博士学位来自哈佛大学和哈佛医学院的博士。 Altshuler博士在马萨诸塞州综合医院完成了内科，内分泌，糖尿病和新陈代谢的临床培训。 Arbuckle是Vertex Pharmaceuticals Incorporated的执行副总裁兼首席商务官，自2012年9月以来一直担任该职位。在加入Vertex Pharmaceuticals Incorporated之前，Arbuckle先生于2004年7月至8月期间在Amgen，Inc.担任多个商业领导职务，Amgen，Inc.是一家拥有17，000人生物技术公司。自1986年以来，Arbuckle先生一直在生物制药行业工作，其中包括在GlaxoSmithKline plc工作超过15年，在那里他担任销售和市场营销职务，负责治疗呼吸，代谢，肌肉骨骼，心血管和其他疾病的药物。他于2015年6月至2017年7月期间担任Cerulean Pharma，Inc.董事会成员，自2018年1月起担任ImmunoGen，Inc.董事会成员。Arbuckle先生拥有药理学学士学位。利兹大学的生理学和生理学。
Stuart A. Arbuckle,As previously announced, Mr. Arbuckle will retire from Vertex effective July 1, 2025. Prior to his role at Vertex, Mr. Arbuckle served as Executive Vice President, Chief Commercial and Operations Officer from March 2021 to July 2021, and as Vertex Pharmaceuticals Incorporated Executive Vice President, Chief Commercial Officer from September 2012 to February 2021. Prior to joining Vertex Pharmaceuticals Incorporated , Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc. from July 2004 through August 2012. Mr. Arbuckle has worked in the biopharmaceuticals industry since 1986, including more than 15 years at GlaxoSmithKline plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He has served as a member of the Board of Directors of Rhythm Pharmaceuticals Inc. since July 2019. He served as a member of the Board of Directors of Cerulean Pharma, Inc. from June 2015 through July 2017 and served as a member of the Board of Directors of ImmunoGen, Inc. from January 2018 until it was acquired by AbbVie Inc. in February 2024. Mr. Arbuckle holds a BSc in Pharmacology and Physiology from the University of Leeds. - Stuart A. Arbuckle，博士，他自2015年1月起担任Vertex Pharmaceuticals Incorporated的全球研究执行副总裁兼首席科学官，并于2012年5月至2014年12月成为Vertex Pharmaceuticals Incorporated的董事会成员。Altshuler博士是Broad Institute的四个创始成员之一，这是一项研究合作哈佛大学，麻省理工学院，怀特黑德研究所和哈佛医院。他于2003年至2014年12月担任该研究所医学和人口遗传学项目主任，并于2009年至2014年12月担任该研究所的副主任和首席学术官。Altshuler博士加入哈佛医学院和马萨诸塞州综合医院2000年至2008年12月担任遗传学和医学教授学术等级。他于2012年至2014年12月在麻省理工学院担任生物学兼职教授。Altshuler博士获得学士学位来自麻省理工学院，获博士学位来自哈佛大学和哈佛医学院的博士。 Altshuler博士在马萨诸塞州综合医院完成了内科，内分泌，糖尿病和新陈代谢的临床培训。 Arbuckle是Vertex Pharmaceuticals Incorporated的执行副总裁兼首席商务官，自2012年9月以来一直担任该职位。在加入Vertex Pharmaceuticals Incorporated之前，Arbuckle先生于2004年7月至8月期间在Amgen，Inc.担任多个商业领导职务，Amgen，Inc.是一家拥有17，000人生物技术公司。自1986年以来，Arbuckle先生一直在生物制药行业工作，其中包括在GlaxoSmithKline plc工作超过15年，在那里他担任销售和市场营销职务，负责治疗呼吸，代谢，肌肉骨骼，心血管和其他疾病的药物。他于2015年6月至2017年7月期间担任Cerulean Pharma，Inc.董事会成员，自2018年1月起担任ImmunoGen，Inc.董事会成员。Arbuckle先生拥有药理学学士学位。利兹大学的生理学和生理学。
- Stuart A. Arbuckle,As previously announced, Mr. Arbuckle will retire from Vertex effective July 1, 2025. Prior to his role at Vertex, Mr. Arbuckle served as Executive Vice President, Chief Commercial and Operations Officer from March 2021 to July 2021, and as Vertex Pharmaceuticals Incorporated Executive Vice President, Chief Commercial Officer from September 2012 to February 2021. Prior to joining Vertex Pharmaceuticals Incorporated , Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc. from July 2004 through August 2012. Mr. Arbuckle has worked in the biopharmaceuticals industry since 1986, including more than 15 years at GlaxoSmithKline plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He has served as a member of the Board of Directors of Rhythm Pharmaceuticals Inc. since July 2019. He served as a member of the Board of Directors of Cerulean Pharma, Inc. from June 2015 through July 2017 and served as a member of the Board of Directors of ImmunoGen, Inc. from January 2018 until it was acquired by AbbVie Inc. in February 2024. Mr. Arbuckle holds a BSc in Pharmacology and Physiology from the University of Leeds.
- Stephen C. McCluski
-
Stephen C. McCluski，在2007年退休之前一直担任博士伦公司高级副总裁兼首席财务官。McCluski先生于1988年加入博士伦，担任前个人产品部门的财务规划和分析总监。1989年被任命为原眼镜事业部副总裁兼财务总监，1992年被任命为公司原Outlook眼镜子公司总裁。1994年被任命为公司副总裁兼财务总监。1995年被任命为高级副总裁兼首席财务官。在加入博士伦之前，他曾在普华永道会计师事务所担任多个职位。McCluski先生是Monro董事会审计委员会主席，也是薪酬、财务、提名和公司治理委员会的成员。他还是ImmunoGen公司的董事会主席，此前曾担任Standard Microsytems Corporation的董事。
Stephen C. McCluski,was Senior Vice President and Chief Financial Officer of Bausch & Lomb Incorporated until his retirement in 2007. Mr. McCluski joined Bausch & Lomb in 1988 as Director - Financial Planning and Analysis for the former Personal Products Division. He was named Vice President and Controller for the former Eyewear Division in 1989, and in 1992, he was named President of the company's former Outlook Eyewear subsidiary. He was named a corporate Vice President and Controller in 1994. He was named Senior Vice President and Chief Financial Officer in 1995. Prior to joining Bausch & Lomb, he held a variety of positions at PricewaterhouseCoopers LLP. Mr. McCluski is Chairman of the Monro Board of Directors' Audit Committee and a member of the Compensation, Finance, and Nominating and Corporate Governance Committees. He also is Chairman of the Board of Directors of ImmunoGen, Inc. and previously served as a Director of Standard Microsytems Corporation. - Stephen C. McCluski，在2007年退休之前一直担任博士伦公司高级副总裁兼首席财务官。McCluski先生于1988年加入博士伦，担任前个人产品部门的财务规划和分析总监。1989年被任命为原眼镜事业部副总裁兼财务总监，1992年被任命为公司原Outlook眼镜子公司总裁。1994年被任命为公司副总裁兼财务总监。1995年被任命为高级副总裁兼首席财务官。在加入博士伦之前，他曾在普华永道会计师事务所担任多个职位。McCluski先生是Monro董事会审计委员会主席，也是薪酬、财务、提名和公司治理委员会的成员。他还是ImmunoGen公司的董事会主席，此前曾担任Standard Microsytems Corporation的董事。
- Stephen C. McCluski,was Senior Vice President and Chief Financial Officer of Bausch & Lomb Incorporated until his retirement in 2007. Mr. McCluski joined Bausch & Lomb in 1988 as Director - Financial Planning and Analysis for the former Personal Products Division. He was named Vice President and Controller for the former Eyewear Division in 1989, and in 1992, he was named President of the company's former Outlook Eyewear subsidiary. He was named a corporate Vice President and Controller in 1994. He was named Senior Vice President and Chief Financial Officer in 1995. Prior to joining Bausch & Lomb, he held a variety of positions at PricewaterhouseCoopers LLP. Mr. McCluski is Chairman of the Monro Board of Directors' Audit Committee and a member of the Compensation, Finance, and Nominating and Corporate Governance Committees. He also is Chairman of the Board of Directors of ImmunoGen, Inc. and previously served as a Director of Standard Microsytems Corporation.
- Dean J. Mitchell
-
Dean J. Mitchell，2009年3月以来，他一直担任董事。他于2013年7月被任命为Covis Pharma Holdings公司（私人专业制药公司，总部位于卢森堡）的执行主席和董事会成员。他也曾担任ImmunoGen公司（公共肿瘤学公司）的非执行董事会成员（2012年以来）。在过去的5年里，他一直担任 ISTA Pharmaceuticals公司和Talecris Biotherapeutics公司的非执行董事会成员（直到它们各自被收购）。他此前曾担任Lux Biosciences公司（一个私人眼科公司）的总裁兼首席执行官和董事会成员（从2010年7月到2013年6月）。此前，他曾担任Alpharma公司（全球专业制药公司）的总裁兼首席执行官，并于2006年7月被任命为其董事会成员。Alpharma公司于2008年12月被King Pharmaceuticals公司收购。他于2008年12月29日退任Alpharma公司的职员兼董事。此前，他曾担任Guilford Pharmaceuticals公司（一家上市公司）的总裁兼首席执行官（从2004年12月到2005年10月）。公司于2005年10月被MGI Pharma公司（公共生物制药公司，专注于肿瘤和急性护理）收购。他曾担任MGI Pharma公司的非执行董事，直到2008年1月公司被Eisai Co。收购。他曾任职Bristol-Myers Squibb公司（上市公司）（从2001年到2004年），担任多种职务，包括负责美国初级保健的国际总裁、战略副总裁。他也曾任职Glaxo SmithKline公司及其前身公司15年，最近担任高级副总裁，负责临床开发和产品策略（从1999年到2001年）。此前，他曾担任副总裁兼总经理，负责专业部门、战略规划和业务发展（从1995年到1999年）。他持有City University Business School（位于英国伦敦）的工商管理硕士学位，以及Coventry University（位于英国）生物学学士学位。他曾担任Alpharma公司、Guilford Pharmaceuticals公司（一家制药公司，为医院和神经学市场生产产品）、MGI Pharma公司、Talecris Biopharmaceuticals公司（所有公司随后均成为上市公司）的董事会成员。
Dean J. Mitchell has served as Executive Chair of the Board of Covis Pharma Holdings, a specialty pharmaceutical company, since 2013 and as Chair of PaxVax Corporation, a specialty vaccine company, from 2016 to 2018. Prior to that, he served as President and Chief Executive Officer of Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, from 2010 to 2013. Prior to that, he served as President and Chief Executive Officer of Alpharma, Inc., a publicly traded human and animal pharmaceutical company, from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008. Prior to that he served as President and Chief Executive Officer of Guilford Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company from 2004 until its acquisition by MGI PHARMA, INC. in 2005. Prior to that he served in various senior executive capacities in the worldwide medicines group of Bristol-Myers Squibb Company, a pharmaceutical company, from 2001 to 2004. Prior to that, he spent 14 years at GlaxoSmithKline plc, a pharmaceutical company, in assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. Mr. Mitchell is also a director of Intrexon, Inc. and Theravance BioPharma, Inc. - Dean J. Mitchell，2009年3月以来，他一直担任董事。他于2013年7月被任命为Covis Pharma Holdings公司（私人专业制药公司，总部位于卢森堡）的执行主席和董事会成员。他也曾担任ImmunoGen公司（公共肿瘤学公司）的非执行董事会成员（2012年以来）。在过去的5年里，他一直担任 ISTA Pharmaceuticals公司和Talecris Biotherapeutics公司的非执行董事会成员（直到它们各自被收购）。他此前曾担任Lux Biosciences公司（一个私人眼科公司）的总裁兼首席执行官和董事会成员（从2010年7月到2013年6月）。此前，他曾担任Alpharma公司（全球专业制药公司）的总裁兼首席执行官，并于2006年7月被任命为其董事会成员。Alpharma公司于2008年12月被King Pharmaceuticals公司收购。他于2008年12月29日退任Alpharma公司的职员兼董事。此前，他曾担任Guilford Pharmaceuticals公司（一家上市公司）的总裁兼首席执行官（从2004年12月到2005年10月）。公司于2005年10月被MGI Pharma公司（公共生物制药公司，专注于肿瘤和急性护理）收购。他曾担任MGI Pharma公司的非执行董事，直到2008年1月公司被Eisai Co。收购。他曾任职Bristol-Myers Squibb公司（上市公司）（从2001年到2004年），担任多种职务，包括负责美国初级保健的国际总裁、战略副总裁。他也曾任职Glaxo SmithKline公司及其前身公司15年，最近担任高级副总裁，负责临床开发和产品策略（从1999年到2001年）。此前，他曾担任副总裁兼总经理，负责专业部门、战略规划和业务发展（从1995年到1999年）。他持有City University Business School（位于英国伦敦）的工商管理硕士学位，以及Coventry University（位于英国）生物学学士学位。他曾担任Alpharma公司、Guilford Pharmaceuticals公司（一家制药公司，为医院和神经学市场生产产品）、MGI Pharma公司、Talecris Biopharmaceuticals公司（所有公司随后均成为上市公司）的董事会成员。
- Dean J. Mitchell has served as Executive Chair of the Board of Covis Pharma Holdings, a specialty pharmaceutical company, since 2013 and as Chair of PaxVax Corporation, a specialty vaccine company, from 2016 to 2018. Prior to that, he served as President and Chief Executive Officer of Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, from 2010 to 2013. Prior to that, he served as President and Chief Executive Officer of Alpharma, Inc., a publicly traded human and animal pharmaceutical company, from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008. Prior to that he served as President and Chief Executive Officer of Guilford Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company from 2004 until its acquisition by MGI PHARMA, INC. in 2005. Prior to that he served in various senior executive capacities in the worldwide medicines group of Bristol-Myers Squibb Company, a pharmaceutical company, from 2001 to 2004. Prior to that, he spent 14 years at GlaxoSmithKline plc, a pharmaceutical company, in assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. Mr. Mitchell is also a director of Intrexon, Inc. and Theravance BioPharma, Inc.
- Mark J. Enyedy
-
Mark J. Enyedy， 曾于2016年5月至2024年2月担任上市生物技术公司ImmunoGen, Inc.的总裁兼首席执行官，当时TERM1，Inc.被艾伯维公司收购。Enyedy从制药公司Shire plc加入ImmunoGen，曾于2013年8月至2016年5月担任各种执行职务，包括2014年5月至2016年5月担任执行副总裁兼企业发展主管。在此之前，他于2011年9月至2013年8月担任生物制药公司Proteostasis Therapeutics, Inc.的首席执行官兼董事。在加入Proteostasis之前，他曾在生物制药公司健赞服务了15年。Enyedy先生在加入健赞之前是波士顿Palmer & Dodge律师事务所的合伙人。Enyedy目前担任Ergomed PLC的私人控股公司Eden Topco Limited的董事。过去五年内，他曾担任Ergomed PLC、LogicBio医疗，Inc.、Akebia Therapeutics, Inc. Enyedy先生的董事。他还曾在Fate Therapeutics, Inc.、Keryx Biopharmaceuticals, Inc.、新英格兰东部美国癌症协会、生物技术创新组织的董事会任职。他拥有东北大学的学士学位和哈佛大学法学院的法学博士学位。
Mark J. Enyedy,served as the President and Chief Executive Officer of ImmunoGen, Inc., a public biotechnology company, from May 2016 until February 2024, when ImmunoGen, Inc. was acquired by AbbVie Inc.Mr. Enyedy joined ImmunoGen from Shire plc, a pharmaceutical company, where he served in various executive capacities from August 2013 to May 2016, including as Executive Vice President and Head of Corporate Development from May 2014 to May 2016. Prior to that, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from September 2011 to August 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company. Before joining Genzyme Corporation, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.Mr. Enyedy currently serves as a director of Eden Topco Limited, a private holding company for Ergomed plc. Within the past five years, he served as a director of Ergomed plc, LogicBio Therapeutics, Inc., and Akebia Therapeutics, Inc. Mr. Enyedy also served on the boards of Fate Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., the American Cancer Society of Eastern New England, and The Biotechnology Innovation Organization.He holds a B.S. from Northeastern University and a J.D. from Harvard Law School. - Mark J. Enyedy， 曾于2016年5月至2024年2月担任上市生物技术公司ImmunoGen, Inc.的总裁兼首席执行官，当时TERM1，Inc.被艾伯维公司收购。Enyedy从制药公司Shire plc加入ImmunoGen，曾于2013年8月至2016年5月担任各种执行职务，包括2014年5月至2016年5月担任执行副总裁兼企业发展主管。在此之前，他于2011年9月至2013年8月担任生物制药公司Proteostasis Therapeutics, Inc.的首席执行官兼董事。在加入Proteostasis之前，他曾在生物制药公司健赞服务了15年。Enyedy先生在加入健赞之前是波士顿Palmer & Dodge律师事务所的合伙人。Enyedy目前担任Ergomed PLC的私人控股公司Eden Topco Limited的董事。过去五年内，他曾担任Ergomed PLC、LogicBio医疗，Inc.、Akebia Therapeutics, Inc. Enyedy先生的董事。他还曾在Fate Therapeutics, Inc.、Keryx Biopharmaceuticals, Inc.、新英格兰东部美国癌症协会、生物技术创新组织的董事会任职。他拥有东北大学的学士学位和哈佛大学法学院的法学博士学位。
- Mark J. Enyedy,served as the President and Chief Executive Officer of ImmunoGen, Inc., a public biotechnology company, from May 2016 until February 2024, when ImmunoGen, Inc. was acquired by AbbVie Inc.Mr. Enyedy joined ImmunoGen from Shire plc, a pharmaceutical company, where he served in various executive capacities from August 2013 to May 2016, including as Executive Vice President and Head of Corporate Development from May 2014 to May 2016. Prior to that, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from September 2011 to August 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company. Before joining Genzyme Corporation, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.Mr. Enyedy currently serves as a director of Eden Topco Limited, a private holding company for Ergomed plc. Within the past five years, he served as a director of Ergomed plc, LogicBio Therapeutics, Inc., and Akebia Therapeutics, Inc. Mr. Enyedy also served on the boards of Fate Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., the American Cancer Society of Eastern New England, and The Biotechnology Innovation Organization.He holds a B.S. from Northeastern University and a J.D. from Harvard Law School.
- Mark Goldberg
-
Mark Goldberg，自2014年1月起担任Synageva BioPharma Corp.（一家生物制药公司）的医疗和监管策略执行副总裁；2011年9月至2014年1月，担任Synageva BioPharma Corp.的医疗和监管事务高级副总裁。1996年至2011年7月间，Goldberg博士在Genzyme Corporation（一家生物技术公司）担任过多个高管职位，最近担任其临床发展高级副总裁、肿瘤学和个性化遗传健康全球治疗组组长。在Genzyme Corporation工作之前，他曾是Brigham and Women’s Hospital 和 Dana Farber Cancer Institute的全职医师，目前仍有其职位。自1996年起，他也是 Harvard Medical School的临床医学助教。 Goldberg博士是一名认证医疗肿瘤学家和血液学家，拥有50多份出版论文。 Goldberg博士也是ImmunoGen, Inc.的董事，早前曾是Synageva BioPharma Corp.的董事。Goldberg博士获得了Harvard College 的学士学位，和Harvard Medical School的医学博士学位。
Mark Goldberg has served as a member of the board of directors of ImmunoGen, Inc. since November 2011 a member of the board of directors of GlycoMimetics, Inc. since July 2014 and as a member of the board of directors of Blueprint Medicines since June 2015. In addition, he is a member of the board of directors of the American Cancer Society, a non-profit organization. Dr. Goldberg previously served on the board of directors of Audentes Therapeutics, Inc. from December 2017 until January 2020 and aTyr Pharma from April 2015 until December 2017. Dr. Goldberg served as advisor and medical and regulatory strategist for Synageva BioPharma Corp., a biopharmaceutical company, from October 2014 until June 2015. Prior to that, he served as the Executive Vice President for Medical and Regulatory Strategy of Synageva from January 2014 to October 2014 and as the Senior Vice President of Medical and Regulatory Affairs of Synageva from September 2011 to January 2014. Dr. Goldberg served in a variety of senior management positions at Genzyme Corporation from 1996 to July 2011 including most recently as Senior Vice President for Clinical Development and Therapeutic Group Head for Oncology and Personalized Genetic Health from 2009 to July 2011. Prior to working at Genzyme Corporation, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute, where he still holds appointments. He has also been an Associate Professor of Medicine at Harvard Medical School since 1996. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Dr. Goldberg holds an A.B. from Harvard College and an M.D. from Harvard Medical School. - Mark Goldberg，自2014年1月起担任Synageva BioPharma Corp.（一家生物制药公司）的医疗和监管策略执行副总裁；2011年9月至2014年1月，担任Synageva BioPharma Corp.的医疗和监管事务高级副总裁。1996年至2011年7月间，Goldberg博士在Genzyme Corporation（一家生物技术公司）担任过多个高管职位，最近担任其临床发展高级副总裁、肿瘤学和个性化遗传健康全球治疗组组长。在Genzyme Corporation工作之前，他曾是Brigham and Women’s Hospital 和 Dana Farber Cancer Institute的全职医师，目前仍有其职位。自1996年起，他也是 Harvard Medical School的临床医学助教。 Goldberg博士是一名认证医疗肿瘤学家和血液学家，拥有50多份出版论文。 Goldberg博士也是ImmunoGen, Inc.的董事，早前曾是Synageva BioPharma Corp.的董事。Goldberg博士获得了Harvard College 的学士学位，和Harvard Medical School的医学博士学位。
- Mark Goldberg has served as a member of the board of directors of ImmunoGen, Inc. since November 2011 a member of the board of directors of GlycoMimetics, Inc. since July 2014 and as a member of the board of directors of Blueprint Medicines since June 2015. In addition, he is a member of the board of directors of the American Cancer Society, a non-profit organization. Dr. Goldberg previously served on the board of directors of Audentes Therapeutics, Inc. from December 2017 until January 2020 and aTyr Pharma from April 2015 until December 2017. Dr. Goldberg served as advisor and medical and regulatory strategist for Synageva BioPharma Corp., a biopharmaceutical company, from October 2014 until June 2015. Prior to that, he served as the Executive Vice President for Medical and Regulatory Strategy of Synageva from January 2014 to October 2014 and as the Senior Vice President of Medical and Regulatory Affairs of Synageva from September 2011 to January 2014. Dr. Goldberg served in a variety of senior management positions at Genzyme Corporation from 1996 to July 2011 including most recently as Senior Vice President for Clinical Development and Therapeutic Group Head for Oncology and Personalized Genetic Health from 2009 to July 2011. Prior to working at Genzyme Corporation, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute, where he still holds appointments. He has also been an Associate Professor of Medicine at Harvard Medical School since 1996. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Dr. Goldberg holds an A.B. from Harvard College and an M.D. from Harvard Medical School.
高管简历
中英对照 | 中文 | 英文- Anna Berkenblit
Anna Berkenblit于2015年加入ImmunoGen，自2019年起担任我们的高级副总裁兼首席医疗官。在此之前，她曾于2015年至2019年担任我们的Vice President兼首席医疗官。在加入ImmunoGen之前，她曾于2013年至2015年担任H3Biomedicine Inc.（一家制药公司）高级副总裁和临床研究主管。Berkenblit博士拥有哈佛医学院（Harvard Medical School）的医学博士学位和哈佛/麻省理工学院（Harvard/MIT）健康与科学临床研究员培训计划硕士学位。Berkenblit博士也是Surrozen，Inc.的董事。
Anna Berkenblit joined ImmunoGen in 2015 and has served as our Senior Vice President and Chief Medical Officer since 2019. Prior to that, she served as our Vice President and Chief Medical Officer from 2015 to 2019. Prior to joining ImmunoGen, she served as Senior Vice President and Head of Clinical Research at H3 Biomedicine Inc., a pharmaceutical company, from 2013 to 2015. Dr. Berkenblit holds a Doctor of Medicine degree from Harvard Medical School and a master’s degree from the Harvard/MIT Health & Sciences clinical investigator training program. Dr. Berkenblit is also a director of Surrozen, Inc.- Anna Berkenblit于2015年加入ImmunoGen，自2019年起担任我们的高级副总裁兼首席医疗官。在此之前，她曾于2015年至2019年担任我们的Vice President兼首席医疗官。在加入ImmunoGen之前，她曾于2013年至2015年担任H3Biomedicine Inc.（一家制药公司）高级副总裁和临床研究主管。Berkenblit博士拥有哈佛医学院（Harvard Medical School）的医学博士学位和哈佛/麻省理工学院（Harvard/MIT）健康与科学临床研究员培训计划硕士学位。Berkenblit博士也是Surrozen，Inc.的董事。
- Anna Berkenblit joined ImmunoGen in 2015 and has served as our Senior Vice President and Chief Medical Officer since 2019. Prior to that, she served as our Vice President and Chief Medical Officer from 2015 to 2019. Prior to joining ImmunoGen, she served as Senior Vice President and Head of Clinical Research at H3 Biomedicine Inc., a pharmaceutical company, from 2013 to 2015. Dr. Berkenblit holds a Doctor of Medicine degree from Harvard Medical School and a master’s degree from the Harvard/MIT Health & Sciences clinical investigator training program. Dr. Berkenblit is also a director of Surrozen, Inc.
- Thomas Ryll
Thomas Ryll于2015年加入ImmunoGen，自2019年以来一直担任我们的高级副总裁，技术运营。在此之前，他于2017年至2019年担任我们的技术运营Vice President，并于受聘之日至2017年担任我们的Vice President，流程和分析开发。在加入ImmunoGen之前，他在生物制药公司Biogen Idec Inc.的前身BiogenInc.工作了近9年，在细胞系培养开发领域担任越来越重要的职务，包括Biogen技术开发部的高级总监。Ryll博士持有德国不伦瑞克技术大学（Technical University of Braunschweig）的生物技术与生物化学博士学位，并在德国the Society for Biotechnology Research（现为the Helmholtz Center for Infection Research）完成博士后工作。
Thomas Ryll joined ImmunoGen in 2015 and has served as our Senior Vice President, Technical Operations, since 2019. Prior to that he served as our Vice President, Technical Operations, from 2017 to 2019 and as our Vice President, Process and Analytical Development, from his date of hire to 2017. Prior to joining ImmunoGen, he spent almost nine years at Biogen Inc. formerly known as Biogen Idec Inc., a biopharmaceutical company, in roles of increasing responsibility in the area of cell line culture development, including Senior Director in Biogen’s technical development department. Dr. Ryll holds a PhD in biotechnology and biochemistry from the Technical University of Braunschweig, Germany, and completed his post-doctoral work at the Society for Biotechnology Research (now the Helmholtz Center for Infection Research) in Germany.- Thomas Ryll于2015年加入ImmunoGen，自2019年以来一直担任我们的高级副总裁，技术运营。在此之前，他于2017年至2019年担任我们的技术运营Vice President，并于受聘之日至2017年担任我们的Vice President，流程和分析开发。在加入ImmunoGen之前，他在生物制药公司Biogen Idec Inc.的前身BiogenInc.工作了近9年，在细胞系培养开发领域担任越来越重要的职务，包括Biogen技术开发部的高级总监。Ryll博士持有德国不伦瑞克技术大学（Technical University of Braunschweig）的生物技术与生物化学博士学位，并在德国the Society for Biotechnology Research（现为the Helmholtz Center for Infection Research）完成博士后工作。
- Thomas Ryll joined ImmunoGen in 2015 and has served as our Senior Vice President, Technical Operations, since 2019. Prior to that he served as our Vice President, Technical Operations, from 2017 to 2019 and as our Vice President, Process and Analytical Development, from his date of hire to 2017. Prior to joining ImmunoGen, he spent almost nine years at Biogen Inc. formerly known as Biogen Idec Inc., a biopharmaceutical company, in roles of increasing responsibility in the area of cell line culture development, including Senior Director in Biogen’s technical development department. Dr. Ryll holds a PhD in biotechnology and biochemistry from the Technical University of Braunschweig, Germany, and completed his post-doctoral work at the Society for Biotechnology Research (now the Helmholtz Center for Infection Research) in Germany.
- Stacy Coen
Stacy Coen于2020年6月加入ImmunoGen，自那时起担任我们的高级副总裁兼首席商务官。科恩女士从生物制药公司Editas Medicine加入ImmunoGen，并于2017年至2020年担任该公司业务发展Vice President。在此之前，她于1997年至2017年在制药公司赛诺菲健赞（Sanofi Genzyme）担任了20年的职务，在业务发展领域的责任不断增加。科恩女士拥有弗吉尼亚大学达顿工商管理研究生院工商管理硕士学位、工商管理硕士学位、金融硕士学位和梦百合。Coen女士目前担任美国亨廷顿疾病协会（The Huntington’；s Disease Society of America）的董事会成员。
Stacy Coen,has served as a member of Fibrobiologics, Inc. board of directors since July 2021. Ms. Coen has over 25 years of business and corporate development experience from leading oncology and rare disease companies. She is currently the Chief Business Officer for ImmunoGen, Inc., a company that is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. Prior to ImmunoGen, Ms. Coen worked at Editas Medicine, Inc., a biotechnology company developing therapies for rare diseases, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions and alliance management. Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme), including as Vice President, Head of Rare Disease Business Development and Licensing, and as Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. Ms. Coen currently serves on the Huntington's Disease Society of America's Center Programs & Education Advisory Committee and is a member of MassBio and the Alliance for Regenerative Medicine. Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University of Virginia.- Stacy Coen于2020年6月加入ImmunoGen，自那时起担任我们的高级副总裁兼首席商务官。科恩女士从生物制药公司Editas Medicine加入ImmunoGen，并于2017年至2020年担任该公司业务发展Vice President。在此之前，她于1997年至2017年在制药公司赛诺菲健赞（Sanofi Genzyme）担任了20年的职务，在业务发展领域的责任不断增加。科恩女士拥有弗吉尼亚大学达顿工商管理研究生院工商管理硕士学位、工商管理硕士学位、金融硕士学位和梦百合。Coen女士目前担任美国亨廷顿疾病协会（The Huntington’；s Disease Society of America）的董事会成员。
- Stacy Coen,has served as a member of Fibrobiologics, Inc. board of directors since July 2021. Ms. Coen has over 25 years of business and corporate development experience from leading oncology and rare disease companies. She is currently the Chief Business Officer for ImmunoGen, Inc., a company that is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. Prior to ImmunoGen, Ms. Coen worked at Editas Medicine, Inc., a biotechnology company developing therapies for rare diseases, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions and alliance management. Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme), including as Vice President, Head of Rare Disease Business Development and Licensing, and as Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. Ms. Coen currently serves on the Huntington's Disease Society of America's Center Programs & Education Advisory Committee and is a member of MassBio and the Alliance for Regenerative Medicine. Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University of Virginia.
- Susan Altschuller
Susan Altshuller于2020年8月加入ImmunoGen，自那时起担任我们的高级副总裁兼首席财务官。加入ImmunoGen公司之前，她曾任职Alexion Pharmaceuticals公司，在那里她曾担任投资者关系主管，在那里她曾担任企业财务主管，在那里她曾领导全球财务报告，并提供投资优先级咨询，以支持公司的战略需求。加入Alexion公司之前，她曾担任Bioverativ公司的投资者关系主管，在那里她曾担任华尔街的主要界面，并领导Biogen公司的衍生产品的所有投资者相关活动。在她的职业生涯早期，Altschuller博士在Biogen担任多个职责递增的职位，包括投资者关系、企业融资和商业融资。Altshuller博士拥有伊利诺伊理工学院（Illinois Institute of Technology）的生物医学工程博士学位和麻省理工学院斯隆管理学院（MIT Sloan School of Management）的工商管理硕士学位。
Susan Altschuller joined ImmunoGen in August 2020 and has served as our Senior Vice President and Chief Financial Officer, since that time. Dr. Altschuller joined ImmunoGen from Alexion Pharmaceuticals, where she served as Head of Investor Relations before moving to Head of Enterprise Finance, where she led global financial reporting and provided counsel on investment prioritization to support the Company's strategic imperatives. Prior to joining Alexion, Dr. Altschuller was Head of Investor Relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen spin-off. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. Dr. Altschuller holds a PhD in Biomedical Engineering from the Illinois Institute of Technology and an MBA from the MIT Sloan School of Management.- Susan Altshuller于2020年8月加入ImmunoGen，自那时起担任我们的高级副总裁兼首席财务官。加入ImmunoGen公司之前，她曾任职Alexion Pharmaceuticals公司，在那里她曾担任投资者关系主管，在那里她曾担任企业财务主管，在那里她曾领导全球财务报告，并提供投资优先级咨询，以支持公司的战略需求。加入Alexion公司之前，她曾担任Bioverativ公司的投资者关系主管，在那里她曾担任华尔街的主要界面，并领导Biogen公司的衍生产品的所有投资者相关活动。在她的职业生涯早期，Altschuller博士在Biogen担任多个职责递增的职位，包括投资者关系、企业融资和商业融资。Altshuller博士拥有伊利诺伊理工学院（Illinois Institute of Technology）的生物医学工程博士学位和麻省理工学院斯隆管理学院（MIT Sloan School of Management）的工商管理硕士学位。
- Susan Altschuller joined ImmunoGen in August 2020 and has served as our Senior Vice President and Chief Financial Officer, since that time. Dr. Altschuller joined ImmunoGen from Alexion Pharmaceuticals, where she served as Head of Investor Relations before moving to Head of Enterprise Finance, where she led global financial reporting and provided counsel on investment prioritization to support the Company's strategic imperatives. Prior to joining Alexion, Dr. Altschuller was Head of Investor Relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen spin-off. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. Dr. Altschuller holds a PhD in Biomedical Engineering from the Illinois Institute of Technology and an MBA from the MIT Sloan School of Management.
- Theresa G. Wingrove
Theresa G. Wingrove，2011年1月加入ImmunoGen，担任规管理事务副总裁。加入ImmunoGen之前，2006年至2011年1月，她担任Histogenics的监管与临床副总裁，这是一个医疗器械公司。她获得了University of Rochester School of Medicine and Dentistry的生化毒理学博士学位，并在University of Rochester Medical Center完成了博士后工作。
Theresa G. Wingrove joined ImmunoGen in 2011 and has served as our Senior Vice President, Regulatory Affairs and Quality since 2018. Prior to that she served as our Vice President, Regulatory Affairs and Quality from 2017 to 2018 and prior to that as our Vice President, Regulatory Affairs for more than five years. Dr. Wingrove holds a PhD in biochemical toxicology from the University of Rochester School of Medicine and Dentistry and completed her postdoctoral work at the University of Rochester Medical Center.- Theresa G. Wingrove，2011年1月加入ImmunoGen，担任规管理事务副总裁。加入ImmunoGen之前，2006年至2011年1月，她担任Histogenics的监管与临床副总裁，这是一个医疗器械公司。她获得了University of Rochester School of Medicine and Dentistry的生化毒理学博士学位，并在University of Rochester Medical Center完成了博士后工作。
- Theresa G. Wingrove joined ImmunoGen in 2011 and has served as our Senior Vice President, Regulatory Affairs and Quality since 2018. Prior to that she served as our Vice President, Regulatory Affairs and Quality from 2017 to 2018 and prior to that as our Vice President, Regulatory Affairs for more than five years. Dr. Wingrove holds a PhD in biochemical toxicology from the University of Rochester School of Medicine and Dentistry and completed her postdoctoral work at the University of Rochester Medical Center.
- Mark J. Enyedy
Mark J. Enyedy， 曾于2016年5月至2024年2月担任上市生物技术公司ImmunoGen, Inc.的总裁兼首席执行官，当时TERM1，Inc.被艾伯维公司收购。Enyedy从制药公司Shire plc加入ImmunoGen，曾于2013年8月至2016年5月担任各种执行职务，包括2014年5月至2016年5月担任执行副总裁兼企业发展主管。在此之前，他于2011年9月至2013年8月担任生物制药公司Proteostasis Therapeutics, Inc.的首席执行官兼董事。在加入Proteostasis之前，他曾在生物制药公司健赞服务了15年。Enyedy先生在加入健赞之前是波士顿Palmer & Dodge律师事务所的合伙人。Enyedy目前担任Ergomed PLC的私人控股公司Eden Topco Limited的董事。过去五年内，他曾担任Ergomed PLC、LogicBio医疗，Inc.、Akebia Therapeutics, Inc. Enyedy先生的董事。他还曾在Fate Therapeutics, Inc.、Keryx Biopharmaceuticals, Inc.、新英格兰东部美国癌症协会、生物技术创新组织的董事会任职。他拥有东北大学的学士学位和哈佛大学法学院的法学博士学位。
Mark J. Enyedy,served as the President and Chief Executive Officer of ImmunoGen, Inc., a public biotechnology company, from May 2016 until February 2024, when ImmunoGen, Inc. was acquired by AbbVie Inc.Mr. Enyedy joined ImmunoGen from Shire plc, a pharmaceutical company, where he served in various executive capacities from August 2013 to May 2016, including as Executive Vice President and Head of Corporate Development from May 2014 to May 2016. Prior to that, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from September 2011 to August 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company. Before joining Genzyme Corporation, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.Mr. Enyedy currently serves as a director of Eden Topco Limited, a private holding company for Ergomed plc. Within the past five years, he served as a director of Ergomed plc, LogicBio Therapeutics, Inc., and Akebia Therapeutics, Inc. Mr. Enyedy also served on the boards of Fate Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., the American Cancer Society of Eastern New England, and The Biotechnology Innovation Organization.He holds a B.S. from Northeastern University and a J.D. from Harvard Law School.- Mark J. Enyedy， 曾于2016年5月至2024年2月担任上市生物技术公司ImmunoGen, Inc.的总裁兼首席执行官，当时TERM1，Inc.被艾伯维公司收购。Enyedy从制药公司Shire plc加入ImmunoGen，曾于2013年8月至2016年5月担任各种执行职务，包括2014年5月至2016年5月担任执行副总裁兼企业发展主管。在此之前，他于2011年9月至2013年8月担任生物制药公司Proteostasis Therapeutics, Inc.的首席执行官兼董事。在加入Proteostasis之前，他曾在生物制药公司健赞服务了15年。Enyedy先生在加入健赞之前是波士顿Palmer & Dodge律师事务所的合伙人。Enyedy目前担任Ergomed PLC的私人控股公司Eden Topco Limited的董事。过去五年内，他曾担任Ergomed PLC、LogicBio医疗，Inc.、Akebia Therapeutics, Inc. Enyedy先生的董事。他还曾在Fate Therapeutics, Inc.、Keryx Biopharmaceuticals, Inc.、新英格兰东部美国癌症协会、生物技术创新组织的董事会任职。他拥有东北大学的学士学位和哈佛大学法学院的法学博士学位。
- Mark J. Enyedy,served as the President and Chief Executive Officer of ImmunoGen, Inc., a public biotechnology company, from May 2016 until February 2024, when ImmunoGen, Inc. was acquired by AbbVie Inc.Mr. Enyedy joined ImmunoGen from Shire plc, a pharmaceutical company, where he served in various executive capacities from August 2013 to May 2016, including as Executive Vice President and Head of Corporate Development from May 2014 to May 2016. Prior to that, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from September 2011 to August 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company. Before joining Genzyme Corporation, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.Mr. Enyedy currently serves as a director of Eden Topco Limited, a private holding company for Ergomed plc. Within the past five years, he served as a director of Ergomed plc, LogicBio Therapeutics, Inc., and Akebia Therapeutics, Inc. Mr. Enyedy also served on the boards of Fate Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., the American Cancer Society of Eastern New England, and The Biotechnology Innovation Organization.He holds a B.S. from Northeastern University and a J.D. from Harvard Law School.